Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells $24,583.02 in Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Lauren Merendino sold 3,927 shares of the company’s stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $6.26, for a total transaction of $24,583.02. Following the completion of the sale, the insider now directly owns 35,161 shares in the company, valued at $220,107.86. This trade represents a 10.05% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Day One Biopharmaceuticals Stock Performance

Shares of NASDAQ DAWN opened at $6.58 on Wednesday. The firm has a market cap of $666.96 million, a P/E ratio of -6.39 and a beta of -1.24. Day One Biopharmaceuticals, Inc. has a 1 year low of $6.08 and a 1 year high of $16.76. The firm’s 50 day moving average price is $7.36 and its 200 day moving average price is $10.68.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.11. The business had revenue of $30.76 million for the quarter, compared to analysts’ expectations of $30.28 million. As a group, equities analysts predict that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Virtus ETF Advisers LLC lifted its stake in shares of Day One Biopharmaceuticals by 7.1% during the 4th quarter. Virtus ETF Advisers LLC now owns 27,296 shares of the company’s stock worth $346,000 after purchasing an additional 1,805 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Day One Biopharmaceuticals by 5.6% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,843 shares of the company’s stock worth $454,000 after purchasing an additional 1,894 shares during the period. GF Fund Management CO. LTD. purchased a new position in shares of Day One Biopharmaceuticals during the 4th quarter worth $27,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Day One Biopharmaceuticals by 11.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 21,383 shares of the company’s stock worth $271,000 after purchasing an additional 2,180 shares during the period. Finally, Exchange Traded Concepts LLC lifted its stake in shares of Day One Biopharmaceuticals by 19.6% during the 1st quarter. Exchange Traded Concepts LLC now owns 14,693 shares of the company’s stock worth $117,000 after purchasing an additional 2,407 shares during the period. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Analyst Ratings Changes

DAWN has been the topic of several recent research reports. Wedbush reaffirmed an “outperform” rating and issued a $25.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday, May 7th. JPMorgan Chase & Co. reduced their price target on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating on the stock in a report on Wednesday, March 5th. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, April 3rd. The Goldman Sachs Group reduced their price target on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating on the stock in a report on Tuesday, March 25th. Finally, Needham & Company LLC reduced their price target on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Day One Biopharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $30.57.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.